[go: up one dir, main page]

AR070800A1 - Proceso para estabilizar una composicion para vacuna que contiene adyuvantes. kit - Google Patents

Proceso para estabilizar una composicion para vacuna que contiene adyuvantes. kit

Info

Publication number
AR070800A1
AR070800A1 ARP090100787A ARP090100787A AR070800A1 AR 070800 A1 AR070800 A1 AR 070800A1 AR P090100787 A ARP090100787 A AR P090100787A AR P090100787 A ARP090100787 A AR P090100787A AR 070800 A1 AR070800 A1 AR 070800A1
Authority
AR
Argentina
Prior art keywords
composition
influenza virus
antigens
process according
microgranules
Prior art date
Application number
ARP090100787A
Other languages
English (en)
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of AR070800A1 publication Critical patent/AR070800A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicacion 1: Un proceso para estabilizar una composicion para vacuna contra la gripe que comprende los pasos de diluir una composicion líquida a granel que comprende un antígeno de la gripe o una preparacion antigénica de una cepa del virus de la gripe estacional, prepandémica o pandémica mediante una solucion acuosa que comprende un carbohidrato y/o un alcohol de azucar o una mezcla de estos para obtener un contenido entre el 2% (p/v) y el limite de solubilidad de los carbohidratos y/o alcoholes de azucar de la composicion diluida obtenida, someter la composicion diluida a un proceso para formar gotitas regulares con un diámetro de entre aproximadamente 200 micrometros y aproximadamente 1500 micrometros, someter las gotitas regulares a congelamiento en un medio congelante para formar microgránulos o partículas esféricos regulares congelados y deshidratar los microgránulos o partículas esféricos regulares congelados para formar microgránulos o partículas esféricos regulares deshidratados con un diámetro de aproximadamente 200 micrometros a aproximadamente 1500 micrometros. Reivindicacion 6: El proceso de acuerdo con cualquiera de las reivindicaciones 1 a 5, en donde la composicion líquida a granel comprende además uno o más antígenos de gripe o preparaciones antigénicas adicionales, cada uno proveniente de una cepa diferente del virus de la gripe estacional, prepandémica o pandémica, para obtener microgránulos o partículas esféricos regulares deshidratados, cada uno comprende dos o más antígenos de gripe o preparaciones antigénicas de dos o más cepas diferentes del virus de la gripe estacional, prepandémica o pandémica. Reivindicacion 10: El proceso de acuerdo con cualquiera de las reivindicaciones 1 a 9, que además comprende la adicion de una solucion acuosa que comprende uno o más adyuvantes y, como opcion, un estabilizador para la composicion de antígenos líquida a granel. Reivindicacion 12: El proceso de acuerdo con las reivindicaciones 10 u 11, en donde el adyuvante pertenece al grupo integrado por liposomas, micelios de lípidos o detergentes u otras partículas lipídicas, nanopartículas o micropartículas poliméricas, polímeros solubles, partículas de proteínas, geles minerales, nanopartículas o micropartículas minerales, nanohíbridos de polímero/aluminio, emulsiones aceite en agua o agua en aceite, extractos de saponina, extractos de la pared celular bacteriana, estimuladores de los receptores de la inmunidad innata, en particular agonistas naturales o sintéticos de TLR, agonistas naturales o sintéticos de NOD y agonistas naturales o sintéticos de RIG. Reivindicacion 13: El proceso de acuerdo con cualquiera de las reivindicaciones 1 a 12, en donde las cepas del virus de la gripe pertenecen al grupo integrado por H5N1, H9N2, H7N7, H2N2, H7N1 y H1N1. Reivindicacion 15: El proceso de acuerdo con cualquiera de las reivindicaciones 1 a 14, en donde el antígeno de la gripe está en una forma perteneciente al grupo integrado por virus entero purificado de la gripe, virus de la gripe o componentes subunitarios del virus de la gripe inactivados. Reivindicacion 16: El proceso de acuerdo con la reivindicacion 15, en donde el virus inactivado de la gripe es un virus ôsplitö (fraccionado) de la gripe. Reivindicacion 33: Una composicion para vacuna, deshidratada, estabilizada que comprende uno o más antígenos cuya composicion es en forma de microgránulos o partículas esféricos regulares deshidratados con un diámetro de aproximadamente 200 ?m a aproximadamente 1500 ?m que se pueden obtener por el proceso de acuerdo con una o más de las reivindicaciones 24 a 32. Reivindicacion 35: La composicion de acuerdo con la reivindicacion 33 en donde cada perla o partícula regular comprende uno o más tipos diferentes de antígenos. Reivindicacion 38: La composicion de acuerdo con cualquiera de las reivindicaciones 33 a 37 en donde el antígeno o los antígenos pertenecen al grupo integrado por virus enteros o componentes antigénicos de virus, vivos, atenuados e inactivados, tales como Polio, Gripe, Rotavirus, citomegalovirus y Hepatitis A y B, y bacterias enteras o antígenos (conjugados o no conjugados) de proteínas o polisacáridos de bacterias, tales como polisacáridos meningococidos, tétanos, difteria, pertussis celular y acelular, botulismo y ántrax.
ARP090100787A 2008-03-05 2009-03-05 Proceso para estabilizar una composicion para vacuna que contiene adyuvantes. kit AR070800A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290216 2008-03-05

Publications (1)

Publication Number Publication Date
AR070800A1 true AR070800A1 (es) 2010-05-05

Family

ID=39678226

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100787A AR070800A1 (es) 2008-03-05 2009-03-05 Proceso para estabilizar una composicion para vacuna que contiene adyuvantes. kit

Country Status (14)

Country Link
US (3) US8551527B2 (es)
EP (2) EP2254594B1 (es)
JP (1) JP5689687B2 (es)
KR (1) KR101695800B1 (es)
CN (2) CN101959527B (es)
AR (1) AR070800A1 (es)
AU (1) AU2009221180B2 (es)
BR (1) BRPI0909820A2 (es)
CA (1) CA2716399C (es)
ES (1) ES2615390T3 (es)
IL (1) IL207308A (es)
MX (1) MX2010008799A (es)
WO (1) WO2009109550A1 (es)
ZA (1) ZA201006225B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
EP1973406B1 (en) 2005-12-28 2014-03-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
JP5285617B2 (ja) 2006-12-18 2013-09-11 アドバンスド バイオニュートリション コーポレーション 生きたプロバイオティクスを含む乾燥食物製品
AU2009221180B2 (en) * 2008-03-05 2014-02-13 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
EP3266448B1 (en) 2009-03-27 2022-02-16 Intervet International B.V. Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
MY157343A (en) 2009-05-26 2016-05-31 Advanced Bionutrition Corp Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
PT2445522T (pt) 2009-06-22 2017-10-04 Wyeth Llc Composições imunogénicas de antigénios de staphylococcus aureus
EP2445523B1 (en) 2009-06-22 2019-04-17 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 8 capsular polysaccharide conjugate immunogenic compositions
WO2011066390A2 (en) * 2009-11-25 2011-06-03 Wildcat Discovery Technologies, Inc. Nanoscale adjuvants and related pharmaceutical compositions and methods
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
ES2639397T3 (es) 2010-01-28 2017-10-26 Advanced Bionutrition Corporation Composición vítrea seca que comprende un material bioactivo
CN107260689A (zh) 2010-04-15 2017-10-20 株式会社新日本科学 用于鼻内递送的方法和组合物
DK3170508T3 (da) 2010-06-04 2020-01-02 Wyeth Llc Vaccineformuleringer
BR112013003244B1 (pt) 2010-08-13 2018-07-17 Advanced Bionutrition Corp composição seca estabilizante para material biológico, seu método de preparação, e formulação de carreamento oral
PT2608805T (pt) 2010-08-23 2017-09-11 Wyeth Llc Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
FR2966044B1 (fr) * 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
CN103826656B (zh) 2010-12-22 2015-08-26 惠氏有限责任公司 金黄色葡萄球菌抗原的稳定的免疫原性组合物
US8549768B2 (en) * 2011-03-11 2013-10-08 Linde Aktiengesellschaft Methods for freeze drying
GB201105981D0 (en) * 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
EP2578975A1 (en) 2011-10-05 2013-04-10 Sanofi Pasteur Sa Rotary drum freeze-dryer
EP2578974A1 (en) * 2011-10-05 2013-04-10 Sanofi Pasteur Sa Process line for the production of freeze-dried particles
UA111631C2 (uk) 2011-10-06 2016-05-25 Санофі Пастер Са Нагрівальний пристрій для роторної барабанної ліофільної сушарки
JP5925342B2 (ja) 2012-03-09 2016-05-25 ファイザー・インク 髄膜炎菌（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）組成物およびその方法
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2905243C (en) 2012-03-14 2021-11-09 Membrane Protective Technologies, Inc. System and substances for cryopreservation of viable cells
GB201212010D0 (en) * 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US20140017318A1 (en) * 2012-07-10 2014-01-16 Kevin O'Connell Method to produce a medicinal product comprising a biologically active protein and the resulting product
US10392420B2 (en) 2012-12-20 2019-08-27 Pfizer Inc. Glycoconjugation process
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
RU2720808C2 (ru) * 2013-09-03 2020-05-13 Джорджия Тек Рисёч Корпорейшн Термостабильные препараты вакцин и микроиглы
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
EP3053594A4 (en) * 2013-10-03 2017-05-10 Nitto Denko Corporation Dried influenza vaccine preparation and method for producing dried influenza vaccine preparation
WO2015057540A1 (en) * 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Method of microwave vacuum drying spherical-shaped pellets of biological materials
CA2927434C (en) 2013-10-16 2022-07-19 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
US10357559B2 (en) * 2013-12-27 2019-07-23 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
CN107073350B (zh) * 2014-07-21 2019-11-15 赛诺菲巴斯德股份公司 用于产生液滴的液体给送装置
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
US10213378B2 (en) * 2015-03-10 2019-02-26 Sporos Therapeutics, LLC Single dose non-adjuvanted cutaneous tetanus vaccine and uses thereof
PL3328215T3 (pl) 2015-07-29 2021-12-13 Advanced Bionutrition Corp. Stabilne suche kompozycje probiotyczne do specjalnych zastosowań dietetycznych
JP6916113B2 (ja) * 2015-11-27 2021-08-11 日東電工株式会社 口腔内投与用ワクチン医薬組成物及び口腔内投与用ワクチン医薬組成物の製造方法
WO2017090769A1 (ja) * 2015-11-27 2017-06-01 日東電工株式会社 インフルエンザワクチン乾燥製剤、及び、インフルエンザワクチン乾燥製剤の製造方法
CN106063933B (zh) * 2015-12-31 2020-01-07 武汉博沃生物科技有限公司 通用疫苗冻干保护剂及其应用
HRP20240433T1 (hr) 2016-09-02 2024-07-05 Sanofi Pasteur, Inc. Cjepivo protiv neisseria meningitidis
MA47223A (fr) 2016-12-30 2019-11-06 Sutrovax Inc Conjugués polypeptide-antigène avec des acides aminés non naturels
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
IL303108B2 (en) 2017-01-31 2024-07-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor
SG11202002174SA (en) 2017-09-13 2020-04-29 Sanofi Pasteur Human cytomegalovirus immunogenic composition
CN111278458A (zh) * 2017-10-25 2020-06-12 默沙东公司 佐剂疫苗
EP3549603A1 (en) 2018-04-06 2019-10-09 Sanofi Pasteur Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same
CN109316603A (zh) * 2018-10-31 2019-02-12 南京大爻网络科技有限公司 一种猪支原体肺炎活疫苗耐热冷冻保护剂、制备方法及应用
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN111658617A (zh) * 2019-10-14 2020-09-15 四川大学 一种含铝佐剂疫苗的冻干制剂及其制备方法和用途
WO2022020815A1 (en) * 2020-07-24 2022-01-27 Soligenix, Inc. Antibody/adjuvant compositions and methods of immune response generation against coronaviruses
AU2021367917A1 (en) 2020-10-28 2023-06-22 Sanofi Pasteur Liposomes containing tlr4 agonist, preparation and uses thereof
CA3211240A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
IL307480A (en) 2021-04-02 2023-12-01 Univ Versailles Saint Quentin En Yvelines An immunogenic preparation containing an antigen and an adjuvant including AL-MOF
IL311906A (en) 2021-10-05 2024-06-01 Sanofi Sa METHODS FOR FREEZING AND FREEZE-DRYING LIPID NANOPARTICLES (LNPs) AND LNPs OBTAINED WITH THE SAME
KR102427362B1 (ko) * 2021-11-11 2022-08-01 (주)이니바이오 보툴리눔 독소 제제의 건조 공정
TW202417038A (zh) 2022-06-15 2024-05-01 法商賽諾菲公司 高度濃縮的抗體組成物

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3162019A (en) 1962-11-16 1964-12-22 Bethlehem Steel Corp Method and apparatus for freezing liquids to be used in a freeze-drying process
GB1195363A (en) 1966-06-17 1970-06-17 Struthers Scientific Int Corp Freeze Drying
US3313032A (en) 1966-07-28 1967-04-11 George J Malecki Freeze-drying process and apparatus
DE1617457A1 (de) * 1966-12-16 1972-04-20 Erba Carlo Spa Verfahren zur Stabilisierung von Zubereitungen interferierender Virusprodukte
US3655838A (en) 1969-03-20 1972-04-11 Organon Method of pelletizing analytical or immunological reagents
US3665838A (en) 1970-01-29 1972-05-30 Wilson Lighting Ltd Air chamber assembly
DE2659546A1 (de) 1976-12-30 1978-07-13 Boehringer Mannheim Gmbh Verfahren zur herstellung von gefrorenen granulaten
US4211015A (en) * 1978-01-18 1980-07-08 Baxter Travenol Laboratories, Inc. Method and apparatus for making novel particulate compositions
FR2505657A1 (fr) 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
ATE14047T1 (de) 1981-12-11 1985-07-15 Wyeth John & Brother Ltd Verfahren und vorrichtung zum gefrieren einer fluessigkeit.
GB8802142D0 (en) 1988-02-01 1988-03-02 Air Prod & Chem Method of freezing liquid & pasty products & freezer for carrying out said method
US4848094A (en) * 1988-04-29 1989-07-18 Union Carbide Corporation Droplet freezing method and apparatus
KR960007749B1 (ko) * 1988-06-21 1996-06-12 아스트라 레케메델 아크티볼라그 제약적으로 유효한 물질의 경구 투여용 액체 제형
CA2051092C (en) 1990-09-12 2002-07-23 Stephen A. Livesey Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
US5776563A (en) * 1991-08-19 1998-07-07 Abaxis, Inc. Dried chemical compositions
DK0604566T3 (da) 1991-09-19 2000-04-10 Us Health Kimærisk og/eller vækstbegrænsede flavivirus
US5307640A (en) 1993-01-25 1994-05-03 E. I. Du Pont De Nemours And Company Apparatus and method for producing frozen particles of a liquid
US5843347A (en) * 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
JPH06323712A (ja) * 1993-04-20 1994-11-25 E I Du Pont De Nemours & Co 霧化した極低温液滴の閉じ込め帯域を用いて凍結粒子を製造する方法および装置
NZ265956A (en) 1993-04-28 1996-09-25 Akzo Nobel Nv Lyospheres containing gonadotropin and compositions thereof
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
AU6093296A (en) 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
FR2742756B1 (fr) 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
IL120202A (en) 1996-03-07 2001-03-19 Akzo Nobel Nv Container with freeze-dried vaccine components
PL192957B1 (pl) 1997-02-28 2006-12-29 Acambis Inc Chimeryczny żywy, zakaźny, atenuowany wirus, jego zastosowanie oraz cząsteczka kwasu nukleinowego kodująca chimeryczny żywy, zakaźny, atenuowany wirus
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
BRPI9701774B8 (pt) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
KR100796220B1 (ko) * 1998-06-29 2008-01-21 넥타르 테라퓨틱스 미립자 전달 시스템 및 사용 방법
US6306404B1 (en) * 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
AU775610B2 (en) * 1998-12-21 2004-08-05 Intervet International B.V. Method to produce inactivated w/o emulsion adjuvated vaccines
JP2002536317A (ja) * 1999-02-03 2002-10-29 パウダージェクト リサーチ リミテッド ヒドロゲル粒子処方物
JP2002540170A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱２型ウイルスワクチン
EP1165131A2 (en) 1999-03-26 2002-01-02 Walter Reed Army Institute of Research Attenuated dengue-1 virus vaccine
EP1165130A2 (en) 1999-03-26 2002-01-02 Walter Reed Army Institute of Research Attenuated dengue-3 virus vaccine
AU4040400A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US6284283B1 (en) 1999-10-21 2001-09-04 Alkermes Controlled Therapeutics, Inc. Method of producing sub-micron particles of biologically active agents and uses thereof
US20040109874A1 (en) * 1999-11-10 2004-06-10 Powderject Vaccines, Inc. Induction of mucosal immunity by vaccination via the skin route
AU2001238441B2 (en) 2000-02-16 2006-10-26 Mahidol University Avirulent, immunogenic flavivirus chimeras
ATE412738T1 (de) 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
US20040213798A1 (en) * 2000-06-08 2004-10-28 Powderject Vaccines, Inc. Spray-dried alum compositions
US20020120228A1 (en) * 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
MXPA02012039A (es) * 2000-06-08 2003-06-06 Powderject Vaccines Inc Composiciones en polvo.
CN100536844C (zh) * 2000-12-07 2009-09-09 尼科梅德有限责任公司 包含酸不稳定活性成分的糊剂形式的药物制剂
WO2002060411A2 (en) 2001-01-30 2002-08-08 Board Of Regents University Of Texas System Process for production of nanoparticles and microparticles by spray freezing into liquid
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
GB2372991B (en) 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
DE10124902A1 (de) 2001-05-22 2002-11-28 Bayer Ag Partikuläre Feststoffe oberflächenaktiver Verbindungen
CA3114957C (en) 2001-05-22 2022-02-08 Stephen S. Whitehead Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
US7569383B2 (en) 2001-06-01 2009-08-04 Acambis Inc. Chimeric flavivirus vectors
BRPI0306905B8 (pt) 2002-01-15 2021-05-25 Acambis Inc método de produção de uma composição imunogênica/dengue que compreende um flavivírus
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
NZ535690A (en) 2002-02-26 2009-04-30 Maxygen Inc Novel flavivirus antigens
WO2003086443A1 (en) * 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
WO2003087339A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
US20040259224A1 (en) 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
GB0225520D0 (en) * 2002-11-01 2002-12-11 Glaxosmithkline Biolog Sa Drying process
KR101150584B1 (ko) 2002-11-15 2012-06-27 사노피 파스테르 바이오로직스 씨오 웨스트 나일 바이러스 백신
US20060002862A1 (en) * 2002-12-17 2006-01-05 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
US20070154494A1 (en) 2003-02-13 2007-07-05 Becton Dickinson And Company Anthrax vaccines and delivery methods
US20040213745A1 (en) * 2003-02-20 2004-10-28 Vincent Sullivan Powder formulations of rSEB for improved vaccination
ES2596553T3 (es) * 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
FR2862306B1 (fr) 2003-11-17 2008-05-30 Aventis Pasteur Composition vaccinale
US7836606B2 (en) 2004-07-23 2010-11-23 Bayer Technology Services Gmbh Sterile freezing, drying, storing, assaying and filling process
CN101027046A (zh) * 2004-09-28 2007-08-29 阿尔扎公司 以明矾为佐剂的免疫活性试剂的稳定化
KR20070057954A (ko) 2004-09-28 2007-06-07 알자 코포레이션 알룸-애주번트가 있는 면역 활성제의 안정화
US20060165717A1 (en) 2005-01-25 2006-07-27 Sanofi Pasteur DCchol in newborns
KR20080018271A (ko) 2005-06-17 2008-02-27 사노피 파스퇴르 약독화된 뎅기 혈청형 2 균주
MX2007015873A (es) 2005-06-17 2008-04-22 Sanofi Pasteur Cepa atenuada de virus de dengue serotipo 1.
AR054822A1 (es) * 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
EP2324850A1 (en) 2005-10-04 2011-05-25 Alk-Abelló A/S Solid vaccine formulation
CN101360821A (zh) 2005-11-21 2009-02-04 圣诺菲·帕斯图尔有限公司 重组病毒的稳定制剂
WO2007073035A1 (en) 2005-12-20 2007-06-28 Samyang Corporation Method for preparing microspheres of polymer and manufacturing apparatus therof
US9521854B2 (en) 2006-05-31 2016-12-20 Air Liquide Industrial U.S. Lp Method and device for creating frozen pellets of a foodstuff
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
US20080226729A1 (en) 2006-09-08 2008-09-18 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
EP1915987A1 (en) 2006-10-27 2008-04-30 MediGene AG Spray-freeze-drying process for the preparation of pellets comprising percolation drying
EP2535058A3 (en) 2006-11-07 2013-04-10 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
EP2036572A1 (en) 2007-09-04 2009-03-18 Novo Nordisk A/S Process for drying a protein, a protein particle and a pharmaceutical composition comprising the protein particle
US8268354B2 (en) * 2007-11-07 2012-09-18 Aridis Pharmaceuticals Sonic low pressure spray drying
AU2009221180B2 (en) * 2008-03-05 2014-02-13 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition

Also Published As

Publication number Publication date
BRPI0909820A2 (pt) 2015-08-11
JP5689687B2 (ja) 2015-03-25
CA2716399C (en) 2020-07-21
CN101959527A (zh) 2011-01-26
ZA201006225B (en) 2011-11-30
KR20110007099A (ko) 2011-01-21
EP2589392B1 (en) 2016-11-30
US9295721B2 (en) 2016-03-29
EP2254594B1 (en) 2015-06-03
US20160235831A1 (en) 2016-08-18
CN105944095A (zh) 2016-09-21
ES2615390T3 (es) 2017-06-06
CN101959527B (zh) 2016-04-20
US9878028B2 (en) 2018-01-30
WO2009109550A1 (en) 2009-09-11
EP2589392A2 (en) 2013-05-08
CN105944095B (zh) 2021-04-02
US20090232894A1 (en) 2009-09-17
IL207308A0 (en) 2010-12-30
US8551527B2 (en) 2013-10-08
KR101695800B1 (ko) 2017-02-22
CA2716399A1 (en) 2009-09-11
EP2254594A1 (en) 2010-12-01
AU2009221180B2 (en) 2014-02-13
JP2011514899A (ja) 2011-05-12
IL207308A (en) 2014-05-28
US20140154329A1 (en) 2014-06-05
EP2589392A3 (en) 2013-08-21
AU2009221180A1 (en) 2009-09-11
MX2010008799A (es) 2010-09-07

Similar Documents

Publication Publication Date Title
AR070800A1 (es) Proceso para estabilizar una composicion para vacuna que contiene adyuvantes. kit
CN104013955A (zh) 一种不含表面活性剂的水包油乳液及其用途
Atmar et al. Adjuvants for pandemic influenza vaccines
MX392585B (es) Particulas similares al virus de la influenza quimericas que comprenden hemaglutinina.
US10874737B2 (en) Influenza nanovaccine
US20170128562A1 (en) Polyvalent influenza virus-like particles (vlps) and use as vaccines
US11510976B2 (en) H7 avian influenza vaccine strain which differentiates infected from vaccinated animals, preparation method therefor, and application
WO2011051235A1 (en) Process for producing influenza vaccine
JP2009514839A5 (es)
CA2825403A1 (en) Vaccines comprising a combination of gamma irradiated influenza virus and a further immunogen
CN110520525A (zh) 用于制备流感工作病毒种苗的方法、用于使用相同种苗制备流感疫苗的方法以及由该方法制备的病毒种苗
US10144917B2 (en) Method for preparing a vaccine antigen, resulting vaccine antigen and uses
US11547754B2 (en) H5 avian influenza vaccine strain which differentiates infected from vaccinated animals, preparation method therefor, and application
WO2011133997A1 (en) Cross-protective influenza vaccines
EP3743107A1 (en) Broadly protective inactivated influenza virus vaccine
Huang et al. Mucosal delivery of a combination adjuvant comprising emulsified fine particles and LD-indolicidin enhances serological immunity to inactivated influenza virus
CN104711291B (zh) 一种预防禽流感病毒感染的新型血凝素抗原的制备及应用
US20240058434A1 (en) Nanoemulsion universal influenza vaccine
Hao et al. Preparation and optimization of a Live Newcastle disease virus vaccine encapsulated in chitosan nanoparticles
WO2016127262A1 (en) Multimerized orthomyxovirus nucleoprotein and uses thereof
Li et al. Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity. Vaccines 2021, 9, 75
Hendy Improved Delivery of a Broadly Active Influenza Subunit Vaccine
CN204814864U (zh) 一种疫苗稀释连接装置
WO2013001124A1 (es) Nanocomposiciones sacarídicas para la liberación de vacunas
Lin et al. Synthetic Virus-like Particles Prepared via Protein Corona Formation Enable Effective Vaccination in an Avian Model of 2 Coronavirus Infection 3

Legal Events

Date Code Title Description
FB Suspension of granting procedure